BlinkLab Limited (ASX:BB1)
Australia
· Delayed Price · Currency is AUD 0.780
-0.055 (-6.59%)
At close: Mar 9, 2026
BlinkLab Company Description
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing.
Its smartphone-based application serves as a device for conducting neurobehavioral evaluations. The company’s application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), and various forms of dementia.
The company was incorporated in 2021 and is based in Perth, Australia.
BlinkLab Limited
| Country | Australia |
| Founded | 2021 |
| Industry | Health Information Services |
| Sector | Healthcare |
| CEO | Hendrikus Boele |
Contact Details
Address: 216 St Georges Tce Perth, Washington 6000 Australia | |
| Phone | 61 2 9068 1925 |
| Website | blinklab.org |
Stock Details
| Ticker Symbol | BB1 |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hendrikus Johannes Boele M.D., Ph.D. | Chief Executive Officer, MD and Director |
| Dr. Anton Uvarov BioChem, MBA, MedGen, Ph.D. | Co-Founder and Executive Director |
| Cornelis Pieter Boele M.A. | Co-Founder and Chief Technology Officer |
| Dr. Sebastiaan K.E Koekkoek Ph.D. | Co-Founder and CSO |
| Seth Sherry | Director of Operations |
| Myrthe Ottenhoff Ph.D. | Chief Medical Officer |
| Christopher Bryan James Achurch B.Com., C.A. | Company Secretary |